What if we could bring the power of precision medicine to more cancer patients, faster—using AI to match patients with the right treatments at the right time?

In this episode, Rick Fultz, CEO of Acurion, shares how his company is transforming precision oncology by combining next-generation science with artificial intelligence to deliver personalized cancer care at scale.

What we discuss:

• The vision behind Acurion and its mission in precision oncology

• How AI and machine learning are revolutionizing cancer treatment selection

• Moving beyond traditional biomarker approaches to comprehensive patient profiling

• Fundraising strategies and building investor confidence in AI-driven healthcare

• Leadership and culture: building a team capable of transforming cancer care

• Challenges and opportunities in scaling precision medicine

• Personal reflections on the future of oncology and patient outcomes

This isn't incremental innovation. This is about fundamentally changing how we match patients with cancer therapies.

About the Guest: Rick Fultz is CEO of Acurion, Inc., a precision oncology company whose mission is to bring the power of precision medicine to more cancer patients, faster.

About the Show: Innovating Tomorrow's Medicine features conversations with biotech leaders, researchers, and innovators who are transforming bold ideas into real-world impact in healthcare and life sciences.

🔗 Connect:

• Acurion: [https://acurionhealth.com]

• Rick Fultz: [https://www.linkedin.com/in/rickfultz]

• Host Jeff Trickett: [https://www.linkedin.com/in/jeff-trickett]

📧 Questions or guest suggestions? [[email protected]]

#Biotech #PrecisionMedicine #Oncology #ArtificialIntelligence #Cancer #MachineLearning #DrugDevelopment #PersonalizedMedicine